• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.

    5/14/25 12:49:48 PM ET
    $FBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    FORTE BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    34962G208

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    34962G208


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    657,509.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    657,509.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    657,509.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    CUSIP No.
    34962G208


    1Names of Reporting Persons

    Janus Henderson Biotech Innovation Master Fund Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    657,509.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    657,509.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    657,509.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IV


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    FORTE BIOSCIENCES, INC.
    (b)Address of issuer's principal executive offices:

    3060 PEGASUS PARK DRIVE, BUILDING 6 DALLAS, TX 75247
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    34962G208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 657,509 shares
    (b)Percent of class:

    9.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    657509

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    657509

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
     
    Janus Henderson Biotech Innovation Master Fund Ltd
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:05/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $FBRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FBRX

    DatePrice TargetRatingAnalyst
    1/21/2025Buy
    TD Cowen
    4/8/2024$2.75Neutral → Buy
    Ladenburg Thalmann
    9/20/2021$4.00 → $3.50Sell → Buy
    Chardan Capital Markets
    9/20/2021$4.00 → $3.50Sell → Neutral
    Chardan Capital
    9/3/2021Buy → Hold
    Brookline Capital
    9/3/2021Buy → Neutral
    Ladenburg Thalmann
    9/3/2021$105.00 → $4.00Buy → Sell
    Chardan Capital Markets
    9/3/2021$4.00Buy → Hold
    Truist
    More analyst ratings

    $FBRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Forte Biosciences, Inc. Announces Results and Provides Update

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2025 financial results and provided a clinical update. "We are looking forward to reading out the topline data from the FB102 celiac disease trial this quarter. FB102 continues to be well-tolerated and there have been no dropouts to date. Additionally, we have now dosed the first patient in the FB102 vitiligo trial. 2025 is shaping up to be a very eventful year which we believe will further validate the potential for FB102," said Forte Biosciences CEO Paul Wagner, Ph.D. Q1 2025 Operating Results Res

      5/15/25 4:01:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences, Inc. Announces Results and Provides Clinical Update

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update. "2024 was a very productive year with significant progress on the development of FB102, including the completion of the healthy volunteer study and the initiation of celiac patient trial," said Forte Biosciences CEO Paul Wagner, Ph.D. "The celiac patient trial is progressing very well. Nearly half of the patients have completed both FB102 dosing and the gluten challenge. FB102 continues to be well-tolerated and there have been no dropouts to date. We are looking f

      3/31/25 9:00:00 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be presenting at the TD Cowen 45th Annual Healthcare Conference hosted at the Boston Marriott Copley Place in Boston, MA. About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing F

      2/3/25 9:00:00 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Forte Biosciences

      TD Cowen initiated coverage of Forte Biosciences with a rating of Buy

      1/21/25 7:45:55 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences upgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75

      4/8/24 7:21:57 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Forte Biosciences from Sell to Buy and set a new price target of $3.50 from $4.00 previously

      9/20/21 7:50:23 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Riley Antony A bought $124,998 worth of shares (22,514 units at $5.55), increasing direct ownership by 273% to 30,776 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      11/22/24 5:45:42 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wagner Paul A. bought $7,525 worth of shares (10,000 units at $0.75), increasing direct ownership by 0.55% to 1,823,236 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      12/20/23 10:56:32 AM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wagner Paul A. bought $14,551 worth of shares (20,520 units at $0.71), increasing direct ownership by 1% to 1,813,236 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      12/15/23 6:29:33 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 154 shares, increasing direct ownership by 0.71% to 31,218 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      4/2/25 5:03:05 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 18 shares, increasing direct ownership by 2% to 79,788 units (SEC Form 4)

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      4/2/25 5:01:48 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gryska David W

      4 - Forte Biosciences, Inc. (0001419041) (Issuer)

      3/21/25 4:51:12 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

      SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      12/6/24 4:05:50 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

      SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      11/14/24 4:31:51 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Forte Biosciences Inc.

      SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      11/14/24 4:02:27 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Financials

    Live finance-specific insights

    See more
    • Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active sub

      9/2/21 4:05:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

      Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Tuesday, September 7th at 8.00 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number is: 13722132. Participants may also

      8/16/21 4:05:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.

      SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)

      5/15/25 7:43:07 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Forte Biosciences Inc.

      10-Q - Forte Biosciences, Inc. (0001419041) (Filer)

      5/15/25 4:05:27 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forte Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Forte Biosciences, Inc. (0001419041) (Filer)

      5/15/25 4:04:16 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

      Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

      6/20/23 8:00:00 AM ET
      $CABA
      $FBRX
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

       -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio

      11/14/22 4:01:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

      -Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi

      11/14/22 4:01:00 PM ET
      $FBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care